Xenon Pharmaceuticals (XENE) Accumulated Expenses (2013 - 2026)

Xenon Pharmaceuticals (XENE) has 14 years of Accumulated Expenses data on file, last reported at $32.5 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 544.07% year-over-year to $32.5 million in Q1 2026; TTM through Mar 2026 was $32.5 million, a 544.07% increase from a year earlier, with the FY2025 full-year figure at $36.4 million, up 201.59% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $32.5 million, down from $36.4 million in the prior quarter.
• Over the last five years, Accumulated Expenses for XENE reached as high as $36.4 million in Q4 2025 and fell as low as $2.1 million in Q1 2022.
• Historically, Accumulated Expenses has averaged $10.3 million across 5 years, with a median of $5.9 million in 2023.
• Across the five-year window, Accumulated Expenses dropped 1.97% in 2022 and jumped 544.07% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $5.8 million in 2022, then soared by 51.54% to $8.8 million in 2023, then soared by 36.68% to $12.1 million in 2024, then soared by 201.59% to $36.4 million in 2025, then dropped by 10.64% to $32.5 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $32.5 million in Q1 2026, $36.4 million in Q4 2025, and $17.5 million in Q3 2025.